Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG200 and Receipt of $50 Million Payment

NEWARK Calif. Aug. 24 2017 PRNewswire Protagonist Therapeutics Inc. Nasdaq PTGX today announced it has closed the worldwide license and collaboration transaction for PTG200 with Janssen Biotech Inc. one of the Janssen Pharmaceutical Companies of Johnson &...